Morphological and immunohistochemical analysis in ovaries and fallopian tubes of tamoxifen, letrozole and clomiphene-treated rats
详细信息 查看全文
- 作者：Suzanne Lima (1)
Alix Clemenson (2)
Beatrice Trombert (3)
Romain Lecointre (4)
Claude-Regis Lacoste (1)
Michel Peoc’h (2)
Gautier Chene (1) (5) - 关键词：Ovulation stimulation ; Ovarian dysplasia ; Ki67 expression ; p53 expression ; Clomid ; Tamoxifen
- 刊名：Archives of Gynecology and Obstetrics
- 出版年：2014
- 出版时间：September 2014
- 年：2014
- 卷：290
- 期：3
- 页码：553-559
- 全文大小：609 KB
- 参考文献：1. Chene G, Dauplat J, Robin N, Caure A, Penault-Llorca F (2013) Tu-be or tu-be: that is the question-About serous ovarian carcinogenesis. Crit Rev Oncol/Hematol 88:134-43 CrossRef
2. Auersperg N (2010) The origin of ovarian carcinomas: a unifying hypothesis. Int J Gynecol Pathol 30:12-1 CrossRef
3. Deligdisch L, Gil J (1989) Characterization of ovarian dysplasia by interactive morphometry. Cancer 63:748-55 CrossRef
4. Deligdisch L, Miranda C, Barba J (1993) Ovarian dysplasia: nuclear texture analysis. Cancer 72:3253-257 CrossRef
5. Chene G, Penault-Llorca F, Le Bouedec G et al (2009) Ovarian epithelial dysplasia and prophylactic oophorectomy for genetic risk. Int J Gynecol Cancer 19:65-2 CrossRef
6. Medeiros F, Muto MG, Lee Y et al (2006) The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 30:230-36 CrossRef
7. Folkins AK, Jarboe EA, Saleemuddin A et al (2008) A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol Oncol 109:168-73 CrossRef
8. Crum CP, Drapkin R, Kindelberger D, Medeiros F, Miron A, Lee Y (2007) Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. Clin Med Res 5:35-4 CrossRef
9. Cibula D, Widschwendter M, Majek O, Dusek L (2011) Tubal ligation and the risk of ovarian cancer: review and meta-analysis. Human Reprod update 17:55-7 CrossRef
10. Nieto JJ, Crow J, Sundaresan M et al (2001) Ovarian epithelial dysplasia in relation to ovulation induction and nulliparity. Gynecol Oncol 82:344-49 CrossRef
11. Chene G, Penault-Llorca F, Le Bouedec G et al (2009) Ovarian epithelial dysplasia after ovulation induction: time and dose effect. Human Reprod 24:132-38 CrossRef
12. Chene G, Penault-Llorca F, Tardieu A et al (2012) Is there a relationship between ovarian epithelial dysplasia and infertility? Obstet Gynecol Int 2012:429085
13. Chene G, Raoelfils I, Dauplat J et al (2012) Don’t forget Fallopian tubes: a morphologic and immunohistochemical study about Fallopian tubes with genetic risk (BRCA mutation). Gynecol Obstet Fertil 40:14-8 CrossRef
14. Brown J, Farquhar C, Beck J, Boothroyd C, Hugues E (2009) Clomiphene and anti-oestrogens for ovulation induction in PCOS. Cochrane Database Syst Rev 4:CD002249
15. Badawy A, Gibreal A (2011) Clomiphene citrate versus tamoxifen for ovulation induction in women with PCOS: a prospective randomized trial. Eur J Obstet Gynecol Reprod Biol 159:151-54 CrossRef
16. Dauplat J, Chene G, Pomel C et al (2009) Comparison of dysplasia profiles in stimulated ovaries and in those with a genetic risk for ovarian cancer. Eur J Cancer 45:2977-983 CrossRef
17. Schloosshauer PW, Cohen CJ, Penault-Lllorca F, Miranda CR, Bignon YJ, Dauplat J, Deligdisch L (2003) Prophylactic oophorectomy. Cancer 98:2599-606 CrossRef
18. Carcangiu ML, Radice P, Manoukian S et al (2003) Atypical epithelial proliferation in Fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA 1 and BRCA 2 germline mutation carriers. Int J Gynecol Pathol 23:35-0 CrossRef
19. Fathalla M (1971) Incessant ovulation: a factor in ovarian neoplasia? Lancet 2:163 CrossRef
20. Celik C, Gezgin? K, Aktan M et al (2004) Effects of ovulation induction on ovarian morphology: an animal study. Int J Gynecol Cancer 14:600-06 CrossRef
21. Corakci A, Filiz S, Caliskan E, Dalcik C, Ozeren S, Dalcik H (2005) The effect of ovulation induction on ovarian epithelium dysplasia score and Ki67 expression: an experimental study on rats. Int J Gynecol Cancer 15:866-71 CrossRef
22. Ozcan Z, Celik H, Gurates B et al (2009) Effects of ovulation induction agents on ovarian surface epithelium in rats. RBM online 19:314-18
23. Lacoste CR, Clemenson A, Lima S, Lecointre R, Peoc’h M, Chene G (2013) Tubo-ovarian dysplasia in relationship with ovulation induction in rats. Fertil Steril 99:1768-773 CrossRef
24. Vicus D, Rosen B, Lubinski J et al (2009) Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers. Gynecol Oncol 115:135-37 CrossRef
25. Swerdlow AJ, Jones ME (2007) Ovarian cancer risk in premenopausal and perimenopausal women treated with tamoxifen: a case-control study. Br J Cancer 96:850-55 CrossRef
26. Cohen I, Beyth Y, Tepper R et al (1996) Ovarian tumors in postmenopausal breast cancer patients treated with tamoxifen. Gynecol Oncol 60:54-8 CrossRef
27. Spicer DV, Pike MC, Henderson BE (1991) Ovarian cancer and long-term tamoxifen in premenopausal women. Lancet 337:1414 CrossRef
28. Ting AY, Kimler BF, Fabian CJ, Petroff BK (2008) Tamoxifen prevents premalignant changes of breast, but not ovarian cancer in rats at high risk for both diseases. Cancer Prev Res 1:546-53 CrossRef
29. Pickel H, Reich O, Tamussino K (1999) Bilateral atypical hyperplasia of the fallopian tube associated with tamoxifen: a report of two cases. Int J Gynecol Pathol 17:284-85 CrossRef
30. Diwan BA, Anderson LM, Ward JM (1997) Proliferative lesions of oviduct and uterus in CD-1 mice exposed prenatally to tamoxifen. Carcinogenesis 18:2009-014 CrossRef
31. Piek JM, van Diest PJ, Zweemer RP (2001) Dysplastic changes in prophylactic removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 195:451-56 CrossRef
32. Cirpan T, Terek MC, Ulukus M, Ulukus EC, Akman L, Kanit L (2008) Immunohistochemical evaluation of cell proliferation and apoptosis markers in ovaries and uterus of tamoxifen-treated rats. Int J Gynecol Cancer 18:141-45 CrossRef
33. Mahdavi A, Pejovic T, Nezhat F (2006) Induction of ovulation and ovarian cancer: a critical review of the literature. Fertil Steril 85:819-26 CrossRef
34. Chene G, Rahimi K, Mes Masson AM, Provencher D (2013) Surgical implications of the potential new tubal pathway for the ovarian carcinogenesis. J Minim Invasive Gynecol 20:153-59 CrossRef - 作者单位：Suzanne Lima (1)
Alix Clemenson (2)
Beatrice Trombert (3)
Romain Lecointre (4)
Claude-Regis Lacoste (1)
Michel Peoc’h (2)
Gautier Chene (1) (5)
1. Department of Obstetric, Gynecology and Reproductive Medicine, CHU Nord, 42000, St Etienne, France
2. Department of Histopathology, CHU Nord, 42000, St Etienne, France
3. Department of Medical Information, CHU Nord, 42000, St Etienne, France
4. Department of Pharmacy of Clinical Oncology, Lyon Sud Hospital, 69000, Lyon, France
5. Department of Gynecology, HFME, Hospices Civils de Lyon, 69000, Lyon, France - ISSN：1432-0711
文摘
Purpose Ovarian and tubal dysplasia may be precursors to ovarian cancer. The goal of this study was to check whether these histopathological lesions would be found after ovulation induction using tamoxifen, clomiphene citrate and letrozole. Methods Seventy-two rats were divided into four groups. In the first group, 24 rats received normal saline. The second group (16 rats) received clomiphene citrate for six cycles. The third group, divided into two sub-groups of eight rats each, were stimulated with tamoxifen for six cycles, with a dosage, respectively, of 0.4 and 0.8?mg/kg/day. In the last group, eight rats received letrozole 0.1?mg/kg/day and eight other rats received letrozole 0.5?mg/kg/day, for six cycles. Once the six cycles had been completed the rats were killed in order to remove ovaries and tubes for histopathological analysis (morphological, p53 and Ki67 immunohistochemical assessment). Results Histopathological lesions were found in both ovaries and tubes. The mean ovarian dysplasia score was significantly higher in the tamoxifen group whatever the dosage (p?=?0.006 and 0.0002) and in the letrozole group with 0.5?mg/kg/day (p?=?0.0002) compared with the control group. The mean tubal dysplasia score was significantly higher in all groups that received drug treatment compared with the control group, whatever the dosage used. The proliferation index (Ki67) was significantly higher in the tamoxifen and letrozole groups while no significant difference was found for apoptosis marker p53. Conclusions Ovulation induction may induce histopathological abnormalities in ovaries and tubes with a different immunohistochemical profile in comparison with salpingo-oophorectomies for genetic risk.